SCHEMBL5423928

SCHEMBL5423928

c1cncc(COc2ccc3[nH]ncc3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.56
DYRK1A Q13627 4/20 0.52
CLK1 P49759 3/20 0.52
CLK4 Q9HAZ1 3/20 0.52
CLK2 P49760 2/20 0.52
DYRK1B Q9Y463 2/20 0.52
CDK2 P24941 2/20 0.52
CLK3 P49761 1/20 0.52
MAOA P21397 1/20 0.50
CDC7 O00311 2/20 0.48
CYP11B1 P15538 1/20 0.48
F9 P00740 1/20 0.47
F10 P00742 1/20 0.47
PIM1 P11309 1/20 0.47
PIM3 Q86V86 1/20 0.47
PIM2 Q9P1W9 1/20 0.47
BRD4 O60885 1/20 0.46
CREBBP Q92793 1/20 0.46
ROCK2 O75116 1/20 0.46
CCR2 P41597 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2570284 0.86 CDC7 (0.61) MAOBDYRK1ACLK1CLK4CLK2
SCHEMBL5415318 0.85 MAOB (0.59) MAOBCLK1MAOACDC7CYP11B1
SCHEMBL18392991 0.81 MAOA (0.50) DYRK1AMAOAF9F10BRD4
SCHEMBL5421994 0.80 MAOB (0.60) MAOBCDC7ROCK2CCR2ROCK1
SCHEMBL28244529 0.80 ALOX5 (0.67) DYRK1AMAOACYP11B1F9F10
SCHEMBL5409358 0.78 MAOB (0.61) MAOBCDC7ROCK2ROCK1
SCHEMBL7832381 0.77 CYP11B2 (0.57) MAOBDYRK1AMAOACYP11B1F9
SCHEMBL28048524 0.77 MAPK1 (0.64) DYRK1AMAOACYP11B1F9F10
SCHEMBL5410948 0.77 CYP4F2 (0.57) MAOBMAOACDC7CYP11B1ROCK2
SCHEMBL17038095 0.77 ROCK2 (0.68) DYRK1ACLK1CLK4CLK2DYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7199147-B2 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-03 US disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA MAOB 2025/4885DYRK1A 900/4885CLK1 982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.